Antivenom compositions and uses thereof

ABSTRACT

Disclosed herein are compositions and methods for treating a victim of a venomous snakebite. Antivenom compositions are prepared from snake plasma or from snake eggs. The antivenom compositions are able to neutralize a snake venom from an autologous snake. The antivenom compositions can be administered to a snakebite victim to treat or prevent the pathological effects of a venomous snakebite.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent application Ser. No. 15/604,524, filed on May 24, 2017, which claims the benefit of and priority to U.S. Provisional Application No. 62/340,983, filed May 24, 2016, each of which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

The subject matter described herein relates to therapeutic compositions derived from snake blood and methods for administering the compositions to victims of venomous snakebites.

BACKGROUND

Snakebites in humans are a neglected public health issue in many tropical and subtropical countries. About five million snakebites occur each year, resulting in up to 2.5 million envenomings (poisoning from snakebites), at least 100,000 deaths and around three times as many amputations and other permanent disabilities. Also, between 150,000 and 300,000 pets are bitten by Crotalids (pit vipers) each year in the USA. Many are put down rather than pay several thousand dollars for treatment.

Antivenom, or more specifically venom antibodies are recognized as the only effective treatment to prevent or reverse most of the venomous effects of venomous bites and stings. A significant challenge in manufacturing of antivenoms is the preparation of the correct immunogens (snake venoms). At present very few countries produce snake venoms of adequate quality for antivenom manufacture. In addition, lack of regulations and proper distribution management for antivenoms in countries with significant snakebite problems results in an inability to assess the quality and appropriateness of the antivenoms.

Autologous and analogous immunity to venoms has been well documented in folklore and science. For example, U.S. Pat. No. 4,150,118 describes the efficacy of a “material extracted from snakes such as snake serum [that] is purified to obtain an inhibitor for snake venom toxicity and/or proteolytic enzymes.” However, the means of antivenom selection and collection was rudimentary.

Disclosed herein is the design and use of an efficient technique and technology to select, collect, purify and isolate autologous snake antivenom. Unlike current venom antibody production, this technology can greatly reduce or entirely eliminate the need for antigens (venom) and their use in hyperimmunization to provide a viable commercial product for treatment of snakebite victims.

SUMMARY

The following aspects and embodiments thereof described and illustrated below are meant to be exemplary and illustrative, not limiting in scope.

In one aspect, a method for treating a subject suffering from a venomous snakebite is provided comprising administering to the subject an antivenom composition comprising plasma obtained from at least one donor snake species.

In some embodiments, the antivenom composition comprises plasma from 1-5, 1-4, 1-3 or 1-2 donor snake species. In some embodiments, the composition comprises plasma from 1, 2 or 3 donor snake species.

In some embodiments, the at least one donor snake species is selected from the group consisting of Kingsnakes (Lampropeltis sp), Python snakes (Python sp), Indigo snakes (Drymarchon sp), Mussuranas (Boiruna sp), Rat snake (Elaphe) or File snakes (Gonionotophis sp).

In some embodiments, the antivenom composition comprises plasma from a first donor snake species and a second donor snake species, wherein the first and second donor snake species are different and are selected from the group consisting of Kingsnakes (Lampropeltis sp), Python snakes (Python sp), Indigo snakes (Drymarchon sp), Mussuranas (Boiruna sp), Rat snake (Elaphe sp) and File snakes (Gonionotophis sp).

In some embodiments, the ratio of the volume of plasma from the first donor snake to the volume of plasma from the second donor snake ranges from about 1:1 to about 10:1, about 1:1 to about 9:1, about 1:1 to about 8:1, about 1:1 to about 7:1, about 1:1 to about 6:1, about 1:1 to about 5:1, about 1:1 to about 4:1, about 1:1 to about 3:1, about 1:1 to about 2:1, about 5:1 to about 10:1, about 2:1 to about 5:1, about 2:1 to about 2:4, or about 2:1 to about 3:1. In some embodiments, the ratio of the volume of plasma from the first donor snake species to the volume of plasma from the second donor snake species is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

In some embodiments, the first snake species is a Python species and the second snake species is a Lampropeltis species.

In some embodiments, the donor snake species is a hybrid snake species, wherein the hybrid snake species is the offspring of two parental snake species from geographically isolated areas.

In some embodiments, the subject was bitten by a rattlesnake. In some embodiments, the rattlesnake is a snake selected from the group consisting of Southern Pacific Rattlesnake (Crotalus oreganus helleri), Western diamondback rattlesnake (C. atrox), Eastern diamondback rattlesnake (C. adamanteus), Pacific rattlesnake (C. viridis viridis), Mojave rattlesnake (C. scutulatus scutulatus), Timber rattlesnake (C. horridus horridus), and Florida ground rattlesnake (Sistrurus miliarius barbouri). In some embodiments, the subject was bitten by a Northern copperhead (Agkistrodon contortrix mokasen), or a Florida cottonmouth (A. piscivorus conanti).

In some embodiments, the subject is a mammal. In some embodiments, the subject is a domesticated animal. Further, in some embodiments, the subject is a dog. Furthermore, in some embodiments, the subject is a human.

In some embodiments, the administering is started within about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 14 hours, about 18 hours, about 20 hours, or about 24 hours after the subject was bitten by the snake.

In some embodiments, the subject is administered a dose of antivenom composition ranging from about 0.1 mL/kg to about 5 mL/kg, about 0.1 mL/kg to about about 4 mL/kg, about 0.1 mL/kg to about 3 mL/kg, about 0.1 mL/kg to about 2 mL/kg, about 0.1 mL/kg to about 1 mL/kg, about 0.2 mL/kg to about 0.5 mL/kg. In some embodiments, about the dose is about 0.1 mL/kg, about 0.2 mL/kg, about 0.3 mL/kg, about 0.4 mL/kg, about 0.5 mL/kg, about 0.6 mL/kg, about 0.7 mL/kg, about 0.8 mL/kg, about 0.9 mL/kg, about 1 mL/kg, about 2 mL/kg, about 3 mL/kg, about 4 mL/kg or 5 mL/kg.

In some embodiments, the administering comprises an intravenous infusion of the antivenom composition in to about the subject. In some embodiments, the infusion is performed at a rate of about 100 mL/hr to about 200 mL/hr, about 100 mL/hr to about 300 mL/hr, about 100 mL/hr to about 150 mL/hr, about 75 mL/hr to about 150 mL/hr, about 5 mL/hr to about 20 mL/hr, about 5 mL/hr to about 15 mL/hr or 5 mL/hr to about 10 mL/hr. In some embodiments, the infusion is performed within a period of about 15 min, about 30 min, about 1 h, about 90 min, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about or 12 hours, or over a period of about 15 min to about 45 min, about 15 min to about 30 min, about 15 min to about 1 hour, about 30 min to about 1 hour, about 1 hour to about 4 hours, or about 30 min to about 6 hours.

In some embodiments, the subject is treated with a second infusion of the antivenom composition. In some embodiments, the second infusion of the antivenom composition is performed within or at about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours after the first infusion.

In some embodiments, the intravenous infusion is continued until the subject achieves a Snake Severity Score (SSS, as discussed further below) of about or below 4, about or below 3, about or below 2, or about or below 1. In some embodiments, the subject achieves a SSS of about or below 4, about or below 3, about or below 2, or about or below 1 within about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours after the intravenous infusion. In some embodiments, the subject achieves a reduction in SSS of about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 within about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 18 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours or about 72 hours after the intravenous infusion.

In some embodiments, the method of treatment is effective in reducing pain, wherein pain is measured using the Glasgow Composite Measure Pain Scale and wherein pain is reduced to a score of 0-3, 1-3, 2-3, or 0, 1, 2 or 3.

In some embodiments, the method of treatment is effective in reducing pain wherein pain is reduced by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% after treatment. In some embodiments, pain reduction is assessed at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, or 2 weeks after any initial or subsequent infusion of the antivenom.

In some embodiments, the method of treatment reduces swelling of the snakebite area by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% compared to swelling at the time the antivenom is administered. In some embodiments, swelling is assessed at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, or 2 weeks after administration of the antivenom.

In some embodiments, the subject is treated with a pain medication. For example, in some embodiments, the pain medication is methadone, fentanyl, or methadone. Further, in some embodiments, the subject is treated with one or more of the pain medications.

In some embodiments, the one or more pain medications is administered to the subject before administration of the antivenom. In some embodiments, the one or more pain medications is administered to the subject during administration of the antivenom. In some embodiments, the one or more pain medications is administered to the subject after administration of the antivenom.

In some embodiments, the subject is treated with an antiemetic. For example, in some embodiments, the antiemetic is maropitant or a pharmaceutical salt thereof.

In some embodiments, the antiemetic is administered to the subject before administration of the antivenom. In some embodiments, the antiemetic is administered to the subject during administration of the antivenom. In some embodiments, the antiemetic is administered to the subject after administration of the antivenom.

In another aspect, a method for preparing an antivenom composition is provided comprising obtaining plasma from the blood of a donor snake and fractionating the plasma to generate the antivenom composition. In some embodiments, the donor snake species is known to be immune to the pathological effects of autologous snake venom.

In some embodiments, the obtaining plasma from the blood of the donor snake comprises bleeding the snake until about 10% to about 20% or about 15% of the snake's blood is transferred to a sterile container.

In some embodiments, the method for preparing an antivenom composition comprises obtaining plasma from the blood of two or more donor snake species, wherein each of the two or more donor snake species is known to be immune to the pathological effects of autologous snake venom.

In some embodiments, the method further comprises isolating plasma from the blood to generate a plasma fraction. In some embodiments, the method further comprises pooling a plurality of the plasma fractions to generate a pool plasma composition.

In some embodiments, the method further comprises incubating the pooled plasma composition with an anticoagulant solution. In some embodiments, the incubating is performed at a temperature of about 2° C. to about 8° C. In some embodiments, the incubating is performed for a time period of about 1 hour to about 4 hours.

In some embodiments, the fractionating the plasma comprises centrifuging the pooled plasma followed by removing the precipitate.

In another aspect, a method for preparing an antivenom composition is provided comprising obtaining plasma from the blood of a venomous snake species and fractionating the plasma to generate the antivenom composition.

In another aspect, a composition is provided comprising a plasma fraction wherein the plasma fraction neutralizes adverse reactions to a venomous snakebite.

In some embodiments, the composition maintains at least about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of its antivenom activity if kept in a sterile container at room temperature. In some embodiments, the composition is kept at room temperature for at least 1 month, 4 months, 6 months, 9 months, 12 months, 18 months, or 1 year, wherein the composition maintains its antivenom activity.

In some embodiments, the antivenom composition further comprises pharmaceutically acceptable excipients.

In some embodiments, the donor snake species is selected from the group consisting of Kingsnakes (Lampropeltis sp), Pythons (Python sp.), Indigo snakes (Drymarchon sp), Mussuranas (Boiruna sp) or File snakes (Gonionotophis sp).

BRIEF DESCRIPTION OF THE DRAWINGS

Various features of illustrative embodiments of the inventions are described below with reference to the drawings. The illustrated embodiments are intended to illustrate, but not to limit, the inventions. The drawings contain the following figures:

FIG. 1 provides a table of example snake species pairs for formulating an antivenom composition described herein.

DETAILED DESCRIPTION

Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.

Definitions

As used in this specification, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “polymer” includes a single polymer as well as two or more of the same or different polymers, reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.

Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 mL to 8 mL is stated, it is intended that 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, and 7 mL are also explicitly disclosed, as well as the range of values greater than or equal to 1 mL and the range of values less than or equal to 8 mL.

The term “antivenom” as used herein means a biological product or composition used in the treatment of venomous bites. An antivenom composition is therapeutically effective to reduce or eliminate the pathological effects of a venomous bit.

The term “therapeutic” as used herein means a treatment and/or prophylaxis. A therapeutic effect is obtained by suppression, remission, or eradication of a pathological state.

As used herein, a “therapeutically effective amount” is an amount required to produce a desired therapeutic effect. For example, in methods for treating a snakebite victim, a therapeutically effective amount is the amount required to reduce swelling by at least 5%, 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 95% within about 2 hours, about 5 hours, about 10 hours, about 12 hours, about 15 hours, about 20 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, or about 72 hours after administration of an antivenom. Alternatively, in methods for treating a snakebite victim, a therapeutically effective amount is the amount required to reduce pain by at least 5%, 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 95% within about 2 hours, 5 hours, 10 hours, 12 hours, 15 hours, 20 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours after administration of an antivenom.

The term “subject” or “patient” as used herein refers to an animal subject (e.g., canine) or a human subject, and may be used interchangeably with “victim” or “snakebite victim.”

Snake Antivenom

The present disclosure relates to the treatment of snakebite victims using a composition that comprises antivenom components from a snake which is naturally resistant to one or more venomous snakes (autologous snake). In accordance with some embodiments disclosed herein, serum from these naturally resistant snakes has been shown to neutralize venom from other venomous species through mortality tests in mice.

Contemplated by the present disclosure are compositions derived from snake blood. Specifically, plasma obtained from the blood of venomous snakes is prepared then further fractionated to produce an antivenom composition. While the venom neutralization properties of certain venomous snakes have been known for centuries, no commercial products have been developed to exploit this property.

Venom-neutralizing properties of autologous snakes have been known since the mid-eighteenth century as many venomous species are immune to their own venoms. Further studies showed that venom neutralization properties of serum from individual snake species are effective against venom of different species of a given genus. For example, Weinstein et al. (J. Herpetology, 1992, 26:452-461) showed that serum from the Lampropeltis genus is able to neutralize venom from Crotaline snakes. Antivenom activity has also been identified in snake eggs (U.S. Pat. No. 4,150,118). However, the biological molecule or molecules responsible for the antivenom activity has not been identified to date and moreover has not been the basis for producing an antivenom therapeutic product for the reliable and convenient clinical treatment of snakebite victims. Described herein are methods for isolating an antivenom composition from the plasma or from the eggs of snakes wherein the composition can be reliably produced and stored as a dependable source for treatment of snakebite victims. Some of the advantages afforded by the compositions and methods include eliminating the need to obtain venom from venomous snakes for hyperimmunization, the need to maintain and immunize large mammals for current antivenom products, and the need to house venomous snakes. Additionally, antivenom compositions prepared from snake plasma and/or eggs are highly adapted to the venoms of venomous snakes, thereby providing broader protection than current antivenoms which are limited by the diversity of venoms which are collected from snakes.

To generate a therapeutic antivenom composition described herein, blood is obtained from a donor snake species such as but not limited to Kingsnake (Lampropeltis sp), Indigo snake (Drymarchon sp), Mussuranas (Boiruna sp), Rat snake (Elaphe) or File snake (Gonionotophis sp). Each donor snake is housed in a quarantined environment and about 15% of its blood taken every 4-6 weeks, preferably every 5 weeks. The need for repeated blood draws from a snake requires reduced stress on the snake as well as the ability to obtain the blood in a manner that ensures sterility. Blood is drawn from the snake into a vacuum tube, maintaining sterility of the blood. The blood is treated with an anticoagulant or blood thinner, such as citrate dextrose, and centrifuged to obtain plasma which can be frozen and pooled for use in therapeutic treatment or for further fractionation.

In a preferred embodiment, the therapeutic antivenom composition is a mixture of plasma obtained from two, three, or more donor snake species. For example, plasma from a first snake species and plasma from a second snake species are pooled into a single antivenom composition. It is understood that the volume ratio of plasma from the first snake species to the plasma from the second snake species can vary. For example, the ratio of first snake species plasma to second snake species plasma can range from about 1:5 to about 5:1, about 1:4 to about 4:1, about 1:3 to about 3:1, about 1:1 to about 2:1, about 1:1 to about 3:1, about 1:1 to about 4:1, or about 1:1 to about 5:1. Likewise, the plasma from a first snake species, the plasma from a second snake species, and the plasma from a third snake species can be pooled together into a single antivenom composition, and the volume ratio of the three plasma components can vary.

The first and second snake species can be selected from Kingsnakes (Lampropeltis sp), Pythons (Python sp.), Indigo snakes (Drymarchon sp), Mussuranas (Boiruna sp), Rat snakes (Elaphe) and File snakes (Gonionotophis sp). In a preferred embodiment, the antivenom composition is a mixture of Kingsnake and Python venom. The first and second snake species can also be selected from a hybrid species as described herein below and exemplified in Table 1. Other therapeutically effective combinations of plasma, at ratios indicated above, include snake species pairs as exemplified in the Table of FIG. 1.

Also described are hybrid snakes for use as donor snakes wherein two snake species which have blood that is therapeutically effective in reducing symptoms of a venomous snakebite are bred. The two parent snakes are geographically isolated such that they would not breed in nature or without human intervention. Examples of such hybrids are presented in Table 1 below. In Table 1, hybrids with 4 “parents” are bred from two snakes that are hybrids themselves. Three parents denotes a hybrid bred with a non-hybrid to produce the resultant hybrid.

TABLE 1 Parent 1 Parent 2 Parent 3 Parent 4 species species Species Species Asphidites Python regius ramsayi Lampropeltis L.t. campbelli californiae L. californiae Pantherophis guttatus L. californiae L.t. hondurensis L. californiae P. guttatus L.m. thayeri P. guttatus L. californiae L. floridana P. alleghaniensis L.t. hondurensis L.t. campbelli Morelia spilota M. spilota M. boeleni variegata L. californiae L.t. campbelli L.t. campbelli L.t. hondurensis

Alternatively, an antivenom composition is obtained from the eggs of donor venomous snakes. In some embodiments, the yolk is treated with caprylic acid to generate a first egg-derived solution containing a therapeutic dose of the antivenom component. The first egg-derived solution can be administered to the snakebite victim or can be further processed to obtain a second egg-derived solution for use in treatment or for further processing. The method for preparing a pharmaceutically effective antivenom composition from snake eggs as described herein provides significant advantages over current methods for preparing antivenom compositions for at least the reason that few reagents and minimal equipment are need for preparation in the field or in the laboratory and can be performed with or without refrigeration.

The antivenom composition is tested for its neutralizing activity prior to packaging for clinical use. The testing is done by mixing the antivenom with venom of the snake for which the antivenom will be labeled. For example, neutralizing activity tests for labeling the product for use in treating a subject bitten by Southern Pacific rattlesnake (Crotalus oreganus helleri) can involve mixing the antivenom with varying amounts of venom isolated from a Southern Pacific rattlesnake (see Example 3), then injecting the mixture into a mouse. The antivenom composition is packaged into a therapeutic dose based on the neutralization activity.

Current antivenoms in the United States for pit vipers and black widow spiders are preserved with mercury, a neurotoxin. The processes and compositions described herein have the added advantage in that use of mercury can be eliminated as it is unnecessary for preservation of the composition which is prepared for clinical use.

The antivenom composition prepared from the host snakes listed above can be therapeutically effective in reducing or eliminating the clinical deterioration and the occurrence of systemic cytotoxicity, neurotoxicity, myotoxicity and hemotoxicity associated with the snakebite. In a preferred embodiment, the victim is treated with the antivenom within 12 hours, 10 hours, 8 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or 1 hour of the bite occurrence. In some embodiments, administration via intravenous infusion to the snakebite victim reduces the SSS to below 3 after infusion of the composition for a period of between about 1-24 hours, between about 1-12 hours, between about 1-10 hours, between about 1-8 hours, between about 2-8 hours, between about 2-5 hours, between about 1-3 hours, between about 0.25-2 hours, between about 15-90 minutes, between about 15-60 minutes, between about 15-30 minutes, between about 15-45 minutes, or over about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 1.5 hours, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, or about 12 hours.

The snakebite victim may also be treated with one or more additional therapeutic agents. For example, the victim may be treated with a pain medication such as tramadol, fentanyl, and/or methadone. The victim may also be treated with an antiemetic such as maropitant citrate. The additional therapeutic agents can also include neostigmine nasal spray. Treatment with additional therapeutic agents can be before, during and/or after administration of an antivenom as described herein.

Prior to treatment, the victim can be assessed and assigned a SSS using the Snake Severity Score method developed by Dart et al. (1996, Ann Emerg Med, 27:321-326). The SSS correlates well with the clinical condition of snakebite victims and provides an objective means for evaluating the severity and progression of envenomation in the victims. Accordingly, a snakebite victim is first evaluated and assigned a SSS. Specifically, the victim is assessed for adverse symptoms of the pulmonary system (e.g., dyspnea, respiratory distress, cyanosis), cardiovascular system (e.g., tachycardia or hypotension), gastrointestinal system (e.g., pain, tenesmus, nausea, vomiting or diarrhea), hematological system (e.g., coagulation) and the central nervous system (e.g., apprehension, headache, weakness, dizziness, chills, confusion, lethargy). The wound site is also assessed for, e.g., pain, swelling or ecchymosis.

The victim can be monitored during and after administration of the antivenom composition with continual reassessment of the SSS to ensure the SSS is decreasing over time and that the victim is not experiencing any new adverse effects which may be due to the antivenom concentration. A therapeutically effective dose of the antivenom composition is one which results in a decrease in the SSS to a score of less than 2 within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours after the start of the administration. In some embodiments, a therapeutically effective dose of the antivenom composition is one which results in a decrease in the SSS to a score of less than 1 within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours after the start of the administration.

Pain experienced by a snakebite may also be assessed or measured using the Glasgow Composite Measure Pain Scale as is known in the art (Holton et al., 2001, Vet Rec., 148:525-531; Reid et al., 2007, Animal Welfare, 16(S):97-104). This pain scale measures pain on a scale of 0-4 based in part on animal behavior such as looking at the wound, licking rubbing and/or chewing the wound or painful area. Accordingly, therapeutically effective treatment of a canine snakebite victim with an antivenom as described herein results in a decrease in pain. For example, a pain score is reduced from 4 to 3, 4 to 2, 4 to 1, or 4 to 0. The period of pain reduction can be about 1 day to 7 days, about 1 day to 5 days, or about 1 day to 3 days.

Other pain scales or assessment means can be used to measure pain reduction upon treatment with an antivenom. Accordingly, therapeutically effective treatment of a snakebite can be one in which pain is reduced by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% when assessed and compared from the time of antivenom administration to the time of assessment. Assessment may be done at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after treatment.

The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.

EXAMPLES

The following examples are illustrative in nature and are in no way intended to be limiting.

Example 1 Preparation of an Antivenom Composition From Snake Blood

To obtain a pharmaceutical composition, quarantined Snake-eating snakes Kingsnakes (Lampropeltis sp), Indigo snakes (Drymarchon sp), Mussuranas (Boiruna sp) or File snakes (Gonionotophis sp) are bled to obtain about 15% of total blood volume or about 1% of total body weight. Snakes are bled using a closed, sterile vacuum blood collection set.

Blood is collected from each animal every 5 weeks. Whole blood is separated into plasma and red blood cells by first treating the blood with anticoagulant solution which is composed of an AB16 (35.6 g sodium citrate, 12.6 g citric acid monohydrate and 51.0 g glucose monohydrate) and anticoagulant citrate dextrose (22.0 g sodium citrate, 8.0 g citric acid, 24.5 g dextrose monohydrate) per 1 L water for injection. The blood and anticoagulant solution are incubated at room temperature for 30 minutes, and then centrifuged at 4500 rpm for 10 minutes at 4° C. The collected plasma is stored in sterile containers at 2° C. to 8° C. until it is pooled for further processing.

Example 2 Preparation of a Combined Antivenom Composition

An antivenom composition was prepared in which plasma from two snakes was obtained and pooled prior to administration to a snakebite victim. First, blood was drawn from the heart of Python snakes and Lampropeltis snakes, placed into a separate tube which was then centrifuged at high speed for 3 minutes. Plasma was drawn off and stored at 4° C. until later use. For each sample from the snakes, a 3 cc syringe and a 1½ inch needle was used to carefully draw plasma away from the hematocrit portion of the blood that has settled to the bottom of the tube, ensuring that the plasma sample did not become contaminated with any hematocrit. The plasma was placed into a vial. Plasma collected from each species was pooled together so that Python plasma was in a first collection vial and Lampropeltis plasma was in a second vial.

The final antivenom composition was prepared to maintain a 3:1 ratio of Python plasma to Lampropeltis plasma. Isoproyl alcohol (91%) was placed on the cap top of each collection vial for sterilization then removed after at least 5 minutes. A syringe and needle were then used to transfer Python plasma into the syringe, and then the same syringe and needle were used to transfer a volume of Lampropeltis plasma into the syringe to produce a 3:1 volume ratio of Python plasma to Lampropeltis plasma. At this point, the syringe was aspirated a bit more to draw a pocket of air into the syringe. The syringe was then inverted repeatedly, allowing the air bubble to move through the syringe from top to bottom, homogenizing the sample and generating the final antivenom ready for administration to a subject.

Example 3

Preparation of an Antivenom Composition from Eggs

An antivenom composition from snake eggs is produced as follows. Yolks are separated from snake eggs are put into a glass beaker. The beaker is placed on a magnetic stirrer with a stir bar and mixed for about 2 minutes to obtain a homogenous suspension. Nine volumes of distilled H₂O is slowly added while stirring is continued over a period of about 5 minutes. The pH of the solution is adjusted to about 5.5 using 1M HCl. Three mL of a solution of caprylic acid is added with vigorous stirring of the solution for about 10 minutes at which time the pH is adjusted to about 4.9 using 1M NaOH. Stirring is continued for approximately 50 min. The mixed solution is filtered using standard Whatman filter paper into a clean 250 mL glass beaker and the pH is adjusted to 7.2±0.2 using 1M NaOH. The protein concentration of the solution is determined using a standard Bradford assay and is stored at −20° C.

Further purification and concentration is achieved by ammonium sulfate precipitation. Under vigorous stirring 22 g solid (NH₄)₂SO₄ per 100 mL of filtrate is slowly added to the filtrate of the caprylic acid precipitation to a final concentration of 20%. Stirring is continued for about 15 min at room temperature. The solution is then transferred to a stirrer at 4° C. and stirring is continued for a minimum of 60 min at 4° C. The solution containing precipitate is then transferred to 50 mL centrifuge tubes and centrifuged for 10 min using a rate of 10000 rpm/8000 g. Centrifugation is conducted at 4° C. The supernatant is discarded and the pellet is dissolved in a minimum volume of Tris Buffered Saline (TBS) (about 2-3 mL). The resultant solution is then dialyzed overnight at 4° C. against 50 volumes of TBS, then filtered through a 0.2 μm filter. The protein concentration of the filtered solution is determined using a standard Bradford assay and purity is assessed using a non-reduced SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and coomassie blue staining. Aliquots of the dialyzed solution are stored at −20° C. or −75° C.

Example 4 Neutralizing Activity of the Antivenom Composition

Neutralizing activity of the antivenom activity prepared from L. getulus according to Example 1 or Example 2 is assessed by mixing the antivenom composition with snake venom then injecting the mixture into mice to test lethality of the mixture. Venom is obtained from Crotalus oreganus helleri (C. o. helleri). A venom dose that contains 4.0 to 21.0 LD₅₀ is mixed with a volume of C. o. helleri antivenom composition as prepared in Example 1 or 2. The plasma-venom mixture is incubated at 37° C. for 45 min, then injected i.p. into mice. Control animals are injected with plasma alone or venom mixed with normal rabbit plasma. Injected animals are observed for 24 hours and mortalities recorded and necropsied. Values representing neutralization potential of a given plasma sample are expressed as the number of LD₅₀ completely neutralized (resulting in 100% survival) by the dose of plasma.

Example 5 Method for Treating a Snakebite Victim

The antivenom composition prepared and characterized according to the foregoing Examples is used to treat a mammal which has been bitten by a venomous snake. A dog which has been bitten by a South Western Rattlesnake is evaluated and assigned a snake severity score. An animal with a score of 3 or greater is administered 10 ml of antivenom by intravenous administration. The animal is monitored throughout the time of infusion. Every hour, the SSS is reevaluated and a thromboelastography test is performed. Infusion is continued until the SSS is less than 3.

Example 6 Treatment of a Snakebite Victim

A canine (Vizsla mix) that was bitten by a snake was treated with antivenom prepared according to Example 2 above. An assessment of the bite and symptoms suggested a rattlesnake bite. The canine was a neutered male, 4 years, 6 months of age, weighing 30.5 kg. Two puncture wounds were located on the medial aspect of the left pelvic limb at the level of the hock. The canine had significant swelling and bruising around the puncture wounds and walked with a notable limp on the left pelvic limb. The canine was treated with 10 mL of antivenom, methadone (0.2 mg/kg IV, q6h), fentanyl (2 mcg/kg/hr CRI), and Cerenia 1 mg/kg IV SID. Within 24 hours of administration of the antivenom, the canine was weight bearing. Within 48 hours the bruising at the site of the wound showed significant improvement. Prior to treatment with the antivenom, the canine had a SSS of 5. Within 24 hours of the treatment with the antivenom, the SSS had decreased to 2.

Further, in another example, a second canine that was bitten by a snake and was treated with antivenom prepared according to Example 2 above. The second canine was a female, 7 years of age, weighing 11.8 kg. An assessment of the bite and symptoms suggested a single rattlesnake bite. A SSS score of 3 was assigned to the second canine. The second canine was treated with 10 mL of antivenom prepared according to Example 2 above, methadone (0.3 mg/kg IV), and tramadol (2 mg/kg Oral, 2-3 times/day as needed). After only 2 hours, the second canine went from having a SSS of 3 to a SSS of 0.

While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended clauses and clauses or claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true spirit and scope.

The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1 or clause 5. The other clauses can be presented in a similar manner.

Clause 1. A method for treating a subject suffering from a venomous snakebite, comprising administering to the subject an antivenom composition comprising plasma components obtained from two or more donor snake species, wherein each donor snake species is a different species and each donor snake species is venomous.

Clause 2. The method of Clause 1, wherein one of the donor snake species is an Eastern Kingsnake (L. g. getulus) or a Python (Python sp).

Clause 3. The method of Clause 1 or 2, wherein the antivenom composition comprises a volume ratio of plasma from a first donor snake species to plasma from a second donor snake species ranging from about 1:1 to 10:1.

Clause 4. The method of Clause 3, wherein the first donor snake species is a Python species and the second donor snake species is a Lampropeltis species and the volume ratio of plasma from the first donor snake species to plasma from the second donor snake species is 3:1.

Clause 5. The method of any one of the preceding Clauses, wherein the method comprises administering a dose of 0.1 mL/kg to 5 mL/kg of the antivenom composition to the subject.

Clause 6. The method of any one of the preceding Clauses, wherein the subject was bitten by a rattlesnake.

Clause 7. The method of Clause 6, wherein the rattlesnake is a Southern Pacific Rattlesnake (Crotalus oreganus helleri).

Clause 8. The method of any one of the preceding Clauses, wherein the subject is a mammal.

Clause 9. The method of any one of the preceding Clauses, wherein the subject is a canine.

Clause 10. The method of any one of Clauses 1-8, wherein the subject is a human.

Clause 11. The method of any one of the preceding Clauses, wherein the administering to the subject comprises intravenous infusion of the antivenom composition.

Clause 12. The method of Clause 11, wherein the administering comprises infusing the composition over a time period of 15 minutes to 3 hours.

Clause 13. The method of any one of the preceding Clauses, wherein prior to the administering the victim has a snakebite severity score (SSS) greater than 3 and wherein the administering comprises infusing the composition into the victim until the SSS is less than 2.

Clause 14. A composition comprising a combination of plasma from two or more snake species, wherein each snake species is different and each snake species is a venomous snake species.

Clause 15 The composition of Clause 14, wherein the combination of plasma is from a first and a second snake species.

Clause 16. The composition of Clause 14, wherein the combination of plasma is from a first and a second and a third snake species.

Clause 17. The composition of Clause 15, wherein the combination of plasma is in a ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species ranging from about 1:1 to about 10:1, about 1:1 to about 9:1, about 1:1 to about 8:1, about 1:1 to about 7:1, about 1:1 to about 6:1, about 1:1 to about 5:1, about 1:1 to about 4:1, about 1:1 to about 3:1, about 1:1 to about 2:1, about 5:1 to about 10:1, about 2:1 to about 5:1, about 2:1 to about 2:4, or about 2:1 to about 3:1.

Clause 18. The composition of Clause 17, wherein the ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

Clause 19. The composition of Clause 18, wherein the ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species is about 3:1.

Clause 20. The composition of any one of Clauses 14 to 19, wherein at least one of the venomous snake species is a member of the genus Lampropeltis sp, Drymarchon sp, Boiruna sp or Gonionotophis sp.

Clause 21. The composition of Clause 19 wherein the first snake species is a Python species and the second snake species is a Lampropeltis species.

Clause 22. The composition of any one of Clauses 14 to 21, wherein the composition was obtained by Caprylic Acid Precipitation.

FURTHER CONSIDERATIONS

In some embodiments, any of the clauses herein may depend from any one of the independent clauses or any one of the dependent clauses. In one aspect, any of the clauses (e.g., dependent or independent clauses) may be combined with any other one or more clauses (e.g., dependent or independent clauses). In one aspect, a claim may include some or all of the words (e.g., steps, operations, means or components) recited in a clause, a sentence, a phrase or a paragraph. In one aspect, a claim may include some or all of the words recited in one or more clauses, sentences, phrases or paragraphs. In one aspect, some of the words in each of the clauses, sentences, phrases or paragraphs may be removed. In one aspect, additional words or elements may be added to a clause, a sentence, a phrase or a paragraph. In one aspect, the subject technology may be implemented without utilizing some of the components, elements, functions or operations described herein. In one aspect, the subject technology may be implemented utilizing additional components, elements, functions or operations.

The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.

There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.

It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.

As used herein, the phrase “at least one of” preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase “at least one of” does not require selection of at least one of each item listed; rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items. By way of example, the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.

Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.

In one or more aspects, the terms “about,” “substantially,” and “approximately” may provide an industry-accepted tolerance for their corresponding terms and/or relativity between items, such as from less than one percent to 10 percent.

The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.

A reference to an element in the singular is not intended to mean “one and only one” unless specifically stated, but rather “one or more.” Pronouns in the masculine (e.g., his) include the feminine and neuter gender (e.g., her and its) and vice versa. The term “some” refers to one or more. Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the subject technology, and are not referred to in connection with the interpretation of the description of the subject technology. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.

Although the detailed description contains many specifics, these should not be construed as limiting the scope of the subject technology but merely as illustrating different examples and aspects of the subject technology. It should be appreciated that the scope of the subject technology includes other embodiments not discussed in detail above. Various other modifications, changes and variations may be made in the arrangement, operation and details of the method and apparatus of the subject technology disclosed herein without departing from the scope of the present disclosure. Unless otherwise expressed, reference to an element in the singular is not intended to mean “one and only one” unless explicitly stated, but rather is meant to mean “one or more.” In addition, it is not necessary for a device or method to address every problem that is solvable (or possess every advantage that is achievable) by different embodiments of the disclosure in order to be encompassed within the scope of the disclosure. The use herein of “can” and derivatives thereof shall be understood in the sense of “possibly” or “optionally” as opposed to an affirmative capability. 

What is claimed is:
 1. A composition comprising a combination of plasma from two or more snake species, wherein each snake species is different and each snake species is a venomous snake species.
 2. The composition of claim 1, wherein the combination of plasma is from a first and a second snake species.
 3. The composition of claim 2, wherein the combination of plasma is in a ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species ranging from about 1:1 to about 10:1.
 4. The composition of claim 2, wherein the ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or 10:1.
 5. The composition of claim 4, wherein the ratio of the volume of plasma from the first snake species to the volume of plasma from the second snake species is about 3:1.
 6. The composition of claim 1, wherein at least one of the snake species is a member of the genus Lampropeltis sp, Drymarchon sp, Boiruna sp or Gonionotophis sp.
 7. The composition of claim 5, wherein the first snake species is a Python species and the second snake species is a Lampropeltis species. 